Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Binetrakin→

Binetrakin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
207137-56-2
Molecular formula
Not available
Molecular weight
Not available
Drug class
Recombinant human interferon gamma (IFN-γ)immunomodulatory cytokine biologic
Mechanism of action
Binds the interferon-gamma receptor and activates JAK1/JAK2-STAT1 signalling, inducing interferon-responsive genes and enhancing macrophage activation and antigen presentation.
Indications / reported uses
  • Potential use in chronic granulomatous disease or other immune disorders depends on the specific interferon gamma product; binetrakin itself has no independently confirmed current marketing authorisation indication in the reviewed sources

Sources: NLM MeSH — Interferon gamma · US DailyMed — ACTIMMUNE (interferon gamma-1b) as a related reference product · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Binetrakin Environmental Risk Assessment (ERA) (the Binetrakin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.